Why Detox Alone May Not Be Enough for Opioid Recovery
DeBinge opioid transition: When travelling to DeBinge in The Bahamas for OLANI treatment, there is no requirement to complete a separate opioid-free waiting window before arrival. DeBinge uses a medically supervised 4-to-5-day buprenorphine transition. Buprenorphine is introduced to bridge the patient away from full-agonist opioids, stabilised and tapered over the first several days, and the O’Neil Long-Acting Naltrexone Implant is typically inserted around day 4 or 5 while buprenorphine is still being tapered. The planned overlap continues as buprenorphine clears and the implant gradually releases naltrexone. This pathway is clinician-supervised because mistimed naltrexone exposure can precipitate withdrawal.
Based on DeBinge’s clinical experience in The Bahamas since 2018, the implant typically provides its strongest craving and relapse-prevention support on average 9 months, while clinically meaningful opioid-receptor blockade may persist for longer, in some patients up to about 15 months. This longer blockade may continue to reduce opioid effects and overdose risk.
Ongoing recovery: The implant is not a cure. The DeBinge programme includes a full year of professional counselling after implantation to address the behavioural and psychological side of addiction.
Opioid detox can be an important first step. It can help a person move through withdrawal and stop regular opioid exposure. But completing detox does not automatically remove opioid cravings, relapse triggers, mental-health problems, environmental risks or the underlying opioid use disorder.
Detox primarily addresses withdrawal. Opioid recovery usually requires a longer-term plan that also addresses cravings, relapse risk, overdose prevention, medication options, counselling, mental health, daily routines and the environment to which the person returns.
Current CDC guidance specifically states that detoxification alone, without medications for opioid use disorder, is not recommended because it is associated with increased risk of returning to opioid use, overdose and overdose death.
Related: If the main barrier is getting from active opioid use onto naltrexone, read our guide to starting opioid recovery and the medically managed transition to naltrexone.
Prepared for Medical Review
Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This article has been prepared as an evidence-informed educational resource and is awaiting formal clinical approval. Until that process has been completed, it should not be described as medically reviewed.
View Dr Fergus Law’s professional profile
Detox Can Solve One Immediate Problem Without Solving Every Recovery Problem
Finishing opioid detox can feel like a major turning point, and it can be. The danger is assuming that the end of withdrawal means the person no longer needs active treatment.
Detoxification is designed primarily to help someone stop opioid use and manage the physical effects of withdrawal.
Opioid use disorder, however, can continue after the acute withdrawal period has ended.
A person may be physically opioid-free while still experiencing cravings, thoughts about opioids, familiar triggers, stress, pain, relationship problems, depression, anxiety or easy access to substances.
Detox may help someone get through the door into recovery. Continuing treatment helps them remain there when ordinary life returns.
In This Guide
- What opioid detox does
- What detox does not automatically treat
- Why guidelines recommend continuing treatment
- Cravings after detox
- Reduced tolerance and overdose risk
- Triggers and environment
- Mental health and pain
- Medication after detox
- Counselling and recovery support
- What should happen after detox?
- Frequently asked questions
- Clinical sources
What Does Opioid Detox Actually Do?
Opioid detoxification, sometimes described more precisely as medically supervised withdrawal, focuses on helping a person discontinue opioids while managing withdrawal and related medical concerns.
Depending on the situation, withdrawal management may involve medication, observation and supportive care.
Withdrawal Symptoms
Treatment can help manage the physical and psychological symptoms that emerge when regular opioid exposure stops.
Immediate Stabilisation
A structured environment can help the person move away from repeated opioid exposure and become medically more stable.
Transition to Further Care
Detox can create an opportunity to move directly into longer-term treatment rather than functioning as a stand-alone intervention.
These are important goals. The problem occurs when detox is treated as if these goals represent the entire treatment of opioid use disorder.
What Does Detox Not Automatically Treat?
Completing withdrawal does not automatically resolve every factor that has been maintaining opioid use.
Cravings
Opioid cravings may continue or return after acute withdrawal has ended.
Learned Triggers
People, places, emotions and routines associated with previous opioid use may continue to activate urges.
Mental-Health Conditions
Anxiety, depression, trauma-related symptoms or other psychiatric problems may still require direct treatment.
Pain
Chronic or acute pain can remain an important recovery issue, especially when opioid use became connected with pain relief.
Recovery Environment
The person may return to the same relationships, neighbourhood, stress and opioid availability that existed before detox.
Overdose Vulnerability
Opioid tolerance may fall during abstinence, potentially making subsequent opioid use more dangerous.
This is why people can relapse after opioid detox even when detoxification itself was completed successfully.
Why Is Detox Alone Not Recommended as Complete OUD Treatment?
CDC guidance recommends offering or arranging evidence-based medication treatment for people with opioid use disorder.
Importantly, CDC states that detoxification by itself, without medications for opioid use disorder, is not recommended because of increased risks of resuming opioid use, overdose and overdose death.
This does not mean that withdrawal management has no value.
It means that withdrawal management should generally be understood as one stage in a wider treatment process rather than the endpoint.
A person can successfully complete detox and still require active treatment for opioid use disorder.
Detox Versus Continuing Opioid Recovery Treatment
| Recovery Need | Detox / Withdrawal Management | Continuing OUD Treatment |
|---|---|---|
| Acute withdrawal | Main focus. | Usually no longer the primary issue once stabilised. |
| Opioid cravings | May improve but can continue. | Medication and behavioural strategies may address ongoing cravings. |
| Relapse triggers | May be reduced temporarily in a controlled setting. | Triggers need to be identified and managed in ordinary life. |
| Medication for OUD | Withdrawal medication may be used. | Buprenorphine, methadone or naltrexone may be considered as ongoing OUD treatment. |
| Mental health | Immediate concerns may be assessed. | Ongoing treatment may be required for psychiatric conditions. |
| Environment | The person may be temporarily removed from normal triggers. | The recovery plan needs to work at home, work and in social situations. |
| Overdose prevention | Tolerance may begin decreasing. | Naloxone access, education and return-to-use planning remain important. |
Cravings Can Continue Even After Physical Withdrawal Improves
One reason detox may not be enough is that acute withdrawal and opioid craving are not the same thing.
A person may no longer be vomiting, sweating, experiencing severe body aches or dealing with other acute withdrawal symptoms and still experience a strong desire to use opioids.
Cravings may be triggered by stress, pain, loneliness, anxiety, conflict, memories or environmental cues associated with previous opioid use.
Read the dedicated guide: How to Stop Opioid Cravings After Detox or Rehab .
Reduced Tolerance Can Increase Overdose Risk
Opioid tolerance can develop during repeated exposure.
Once opioids are stopped, tolerance can decrease. If a person later returns to an amount similar to what they used before detox, that amount may have substantially stronger effects.
Repeated Use
Opioid tolerance may develop.
Detox
Regular exposure stops.
Abstinence
Tolerance may decrease.
Return to Use
A previous amount may now have stronger effects.
Overdose
Respiratory depression can become life-threatening.
Where opioid exposure remains possible, naloxone should be available and people close to the patient should understand how to respond to a suspected opioid overdose.
See the complete explanation of overdose risk after detox and reduced opioid tolerance .
The Same Triggers May Be Waiting When the Person Returns Home
During detox, access to opioids may be restricted and the person’s daily environment may temporarily become more controlled.
Returning home can reintroduce the same circumstances that were associated with opioid use before treatment.
People
Friends, partners or contacts associated with previous opioid use may still be present.
Places
Familiar streets, homes and neighbourhoods may activate learned opioid-use patterns.
Stress
Employment, finances, family responsibilities and relationship problems can return immediately.
Isolation
Long periods alone can make cravings and repetitive opioid thoughts harder to interrupt.
Easy Access
Previous suppliers or purchasing routes may still be accessible.
Other Substance Use
Alcohol or other drugs may reduce judgment and reconnect the person with high-risk situations.
This is why identifying opioid relapse triggers is an important part of planning beyond detox.
Detox Does Not Automatically Treat Depression, Anxiety, Trauma or Pain
Some people have used opioids partly in response to problems that continue after withdrawal.
- depression;
- anxiety;
- trauma-related symptoms;
- insomnia;
- chronic pain;
- relationship conflict;
- loneliness;
- work or financial stress.
If those problems remain untreated, the pressure that previously contributed to opioid use may still exist.
This is why psychiatric assessment, psychological treatment, appropriate pain management and wider social support can be important parts of opioid recovery.
Medication Can Continue Treatment Beyond Detox
The FDA currently recognises three medications for treatment of opioid use disorder: buprenorphine, methadone and naltrexone.
Each works differently and should be considered according to the individual’s clinical circumstances.
Buprenorphine
Buprenorphine can reduce withdrawal symptoms and opioid cravings and can be used as ongoing treatment for opioid use disorder.
Methadone
Methadone can reduce opioid cravings and withdrawal and is an established maintenance treatment for opioid use disorder.
Naltrexone
Naltrexone blocks opioid receptors and requires appropriate opioid-free preparation before treatment begins.
Treatment choice depends on current opioid exposure, dependence, previous treatment, patient preferences, medical circumstances, treatment access and other individual factors.
The flagship guide compares medication options used as part of opioid relapse prevention .
Naltrexone After Opioid Detox
Naltrexone works differently from methadone and buprenorphine because it is an opioid receptor antagonist rather than an opioid agonist.
It can block or substantially reduce opioid effects while adequate medication levels are present.
Naltrexone must be started only after appropriate opioid-free preparation. Beginning antagonist treatment while significant opioid physical dependence remains can precipitate withdrawal.
Attempting to overcome opioid blockade by taking larger quantities can be dangerous. Overdose vulnerability may also increase as antagonist effects decline after a period of reduced opioid tolerance.
What About Long-Acting Naltrexone?
Longer-acting formulations may reduce dependence on repeated daily medication decisions.
That may be relevant where adherence is an important vulnerability, but medication does not replace counselling, mental-health treatment, environmental change, family involvement or recovery planning.
Naltrexone implant formulations are not FDA-approved for routine clinical use in the United States. DeBinge treatment involving long-acting implant-based naltrexone takes place in Nassau, The Bahamas, following individual assessment.
Learn more: Long-Acting Naltrexone Implant .
Counselling and Recovery Support Address Problems Detox Cannot
Medication can be important, but treatment also needs to prepare the person for everyday life.
Trigger Planning
Identify the people, places, emotions and circumstances most likely to increase opioid-use risk.
Craving Management
Prepare a specific response for strong cravings before they happen.
Coping Skills
Develop alternatives for managing stress, emotional distress, conflict and other difficult experiences.
Relationships
Review boundaries and relationships associated with previous opioid use or recovery instability.
Daily Structure
Build predictable routines around sleep, work, appointments and previously vulnerable times.
Early Intervention
Decide what should happen if cravings increase, appointments are missed or opioid use returns.
See: Medically Supervised Relapse Prevention: What Happens After Detox or Rehab?
What Should Happen After Opioid Detox?
The details depend on the individual, but continuing recovery planning should ideally begin before detox ends.
Arrange continuing OUD treatment
Avoid an unnecessary gap between withdrawal management and the next stage of treatment.
Review medication options
Discuss buprenorphine, methadone or naltrexone with an appropriately qualified clinician where relevant.
Create a craving plan
Decide what the person will do when a strong opioid craving appears.
Identify personal relapse triggers
Focus on the specific people, places, situations and emotions associated with previous opioid use.
Review mental-health needs
Address depression, anxiety, trauma, sleep problems or other psychiatric symptoms where indicated.
Assess the home environment
Consider whether the person is returning to easy opioid access, high-risk relationships or other major relapse pressures.
Keep naloxone available
Reduced tolerance can make opioid return-to-use particularly dangerous after abstinence.
Plan for a return to use
Decide in advance how to respond safely and quickly if opioid use occurs again.
If Detox Is Only the Beginning, How Do You Prevent Opioid Relapse?
Continuing recovery involves more than completing withdrawal. Medication, cravings, triggers, counselling, mental health, environment, family support, overdose prevention and early response all form part of the wider relapse-prevention plan.
A Return to Use Does Not Mean Detox Was Pointless
If opioid use happens after detox, it may show that the wider treatment plan needs to be strengthened or changed.
Immediate safety comes first because reduced tolerance may increase overdose risk.
Give naloxone if available, contact emergency services immediately and remain with the person until professional help arrives.
Once immediate safety has been addressed, reconnect with treatment and review medication, cravings, triggers, mental health, treatment attendance and the recovery environment.
Plan Beyond Withdrawal
DeBinge provides addiction treatment in Nassau, The Bahamas. For suitable patients, assessment may include discussion of long-acting naltrexone alongside counselling and continuing recovery planning.
Suitability depends on current opioid exposure, detox status, medical history, medications, previous treatment, relapse history and individual recovery goals.
Opioid Detox and Recovery: FAQs
Is opioid detox enough for recovery?
Detox can be an important step, but it is not generally considered complete treatment for opioid use disorder. Continuing treatment may include medication, counselling, mental-health care, relapse-prevention planning and overdose prevention.
Why does CDC say detox alone is not recommended?
CDC states that detoxification alone without medications for opioid use disorder is associated with increased risks of returning to opioid use, overdose and overdose death.
Can someone relapse even after successfully completing detox?
Yes. Detox can successfully manage withdrawal while cravings, triggers, mental-health problems and environmental risk remain present.
Why are opioids more dangerous after detox?
Opioid tolerance may decrease during abstinence. Returning to an amount previously tolerated may therefore increase overdose risk.
What medications can be used after opioid detox?
FDA-approved medications for opioid use disorder include buprenorphine, methadone and naltrexone. The appropriate treatment depends on individual clinical circumstances.
Does medication replace counselling?
Medication and counselling address different parts of recovery. Medication may reduce withdrawal, cravings or opioid effects depending on the treatment, while counselling can address triggers, behaviour, relationships, coping and other recovery needs.
Can naltrexone be started immediately after opioid detox?
Naltrexone requires an appropriate opioid-free period before initiation. Starting it while significant opioid dependence remains can precipitate withdrawal, so timing should be determined clinically.
Are naltrexone implants FDA-approved in the United States?
No. Naltrexone implant formulations are not FDA-approved for routine clinical use in the United States.
What should be arranged before someone finishes opioid detox?
Where possible, continuing treatment, medication review, counselling, overdose planning, naloxone access, mental-health support and a practical recovery plan should be considered before the person returns to ordinary life.
What if someone uses opioids again after detox?
Address overdose safety first and seek emergency help when necessary. Then reconnect with treatment promptly rather than assuming all previous progress has been lost.
Evidence Used in This Guide
CDC — Opioid Use Disorder: Treating
CDC guidance explaining the role of medications for opioid use disorder and why detoxification alone is not recommended as complete OUD treatment.
CDC — Clinical Practice Guideline
CDC Recommendation 12 advises clinicians to offer or arrange evidence-based medications for patients with opioid use disorder.
FDA — Medications for Opioid Use Disorder
Current FDA information on buprenorphine, methadone and naltrexone as approved medications for treatment of opioid use disorder.
SAMHSA — TIP 63: Medications for Opioid Use Disorder
SAMHSA’s Treatment Improvement Protocol reviews methadone, buprenorphine and naltrexone as well as other services that support recovery from opioid use disorder.
Clinical guidance, medication approvals and regulatory information can change. Patients should confirm current information with their treating clinician and the relevant healthcare regulator.
Related: If the main barrier is getting from active opioid use onto naltrexone, read our guide to starting opioid recovery and the medically managed transition to naltrexone.
Prepared for Medical Review
Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This article has been prepared as an educational resource concerning opioid detoxification, continuing treatment, medication and relapse prevention. It is awaiting formal clinical approval.
View Dr Fergus Law’s professional profile
This Article Does Not Replace Individual Medical Care
This page provides general educational information. It does not diagnose opioid use disorder, determine treatment suitability or recommend a specific medication for an individual.
Do not abruptly stop methadone, buprenorphine, prescribed opioids or another prescribed medication based on this article. Medication changes and withdrawal can require medical supervision.
Naltrexone should not be started while significant opioid physical dependence remains. Appropriate opioid-free preparation and individual clinical assessment are required.
If someone is unconscious, cannot be awakened, has very slow or stopped breathing, or an opioid overdose is suspected, administer naloxone if available and contact local emergency services immediately.
DeBinge is located in Nassau, The Bahamas. We do not operate a treatment facility in the United States. Naltrexone implant formulations are not FDA-approved for routine clinical use in the United States.